Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab

DOI Web Site PubMed
  • TATEKOSHI Ayumi
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • SATO Tsutomu
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • IBATA Soushi
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • HASHIMOTO Akari
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • KAMIHARA Yusuke
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • HORIGUCHI Hiroto
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • ONO Kaoru
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • TAKADA Kohichi
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • IYAMA Satoshi
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • TAKIMOTO Rishu
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • KOBUNE Masayoshi
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine
  • KATO Junji
    Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine

Bibliographic Information

Other Title
  • ゾレドロン酸からデノスマブに切り替えた多発性骨髄腫における骨代謝マーカーの検討
  • 臨床研究 ゾレドロン酸からデノスマブに切り替えた多発性骨髄腫における骨代謝マーカーの検討
  • リンショウ ケンキュウ ゾレドロンサン カラ デノスマブ ニ キリカエタ タハツセイ コツズイシュ ニ オケル ホネ タイシャ マーカー ノ ケントウ

Search this article

Abstract

To date, intravenous drip infusion of zoledronic acid (ZA) has mainly been used for the treatment and prevention of skeletal-related events (SRE) in patients with multiple myeloma (MM). Recently, denosumab, a fully humanized monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), has also become available for the same purpose, but little is known about the impact of switching from ZA to denosumab. Herein, we present a retrospective study on bone metabolic markers in 10 MM patients initially treated with ZA and then switched to denosumab. Consequently, the levels of bone resorption markers, tartrate-resistant acid phosphatase 5b (TRACP-5b) and serum type-I collagen crosslinked N-telopeptide (sNTX), significantly decreased after denosumab treatment, while the levels of bone formation markers, osteocalcin (OC) and bone-specific alkaline phosphatase (BAP), showed no apparent changes. No patient developed severe hypocalcemia with denosumab treatment. In one patient not given chemotherapy, the M-protein level increased after switching from ZA to denosumab and plateaued when ZA was restarted. Based on this finding, we anticipate that switching from ZA to denosumab would exert a stronger suppressive effect on osteoclasts, but the anti-myeloma activity of ZA must be taken into consideration.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 55 (11), 2271-2276, 2014

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top